C&R Research Inc. (KOSDAQ:359090)
South Korea · Delayed Price · Currency is KRW 772.00
-30.00 (-3.74%)
At close: Apr 2, 2026
C&R Research Revenue
In the year 2025, C&R Research had annual revenue of 64.98B KRW with 8.87% growth. C&R Research had revenue of 15.21B in the quarter ending December 31, 2025, with 7.11% growth.
Revenue
64.98B
Revenue Growth
+8.87%
P/S Ratio
0.68
Revenue / Employee
127.42M
Employees
510
Market Cap
44.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 64.98B | 5.29B | 8.87% |
| Dec 31, 2024 | 59.69B | 4.59B | 8.32% |
| Dec 31, 2023 | 55.10B | 6.63B | 13.68% |
| Dec 31, 2022 | 48.47B | 5.30B | 12.28% |
| Dec 31, 2021 | 43.17B | 15.97B | 58.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB bioStep | 74.05B |
| DreamCIS | 62.06B |
| DT&CRO CO. | 47.75B |
| WOOJUNG BIO | 37.59B |
| BioInfra | 23.15B |
| P&K Skin Research Center | 22.78B |
| Penetrium Bioscience | 9.74B |
| Curachem | 6.02B |